Skip to content

Application of cyclopofol-affentanil in short surgery in urology

Comparison of different anesthesia methods in general anesthesia of urology department

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200056580
Enrollment
Unknown
Registered
2022-02-08
Start date
2023-03-31
Completion date
Unknown
Last updated
2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Group C:Use cyclopofol sedation

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years, regardless of gender; 2. American Anesthesiologist Classification (ASA) Grade I-II; 3. Body mass index (BMI) >=18 and <= 30kg/m2; 4. Able to understand the research process and methods, and willing to participate in the research.

Exclusion criteria

Exclusion criteria: 1. Those who have contraindications to general anesthesia or have a history of anesthesia accidents in the past; 2. Known or suspected allergy or contraindication to propofol injection, cyclopofol injection excipients, benzodiazepines, opioids, muscle relaxants, etc.; 3. Patients with brain loss, intracranial hypertension, stroke, unstable angina pectoris and myocardial infarction; 4. Respiratory insufficiency, obstructive pulmonary disease, difficult airway, or determination of difficulty in endotracheal intubation (Modified Martensite score: Grade III or Grade IV); 5. Uncontrolled diabetes or hypertension; 6. Severe liver dysfunction or severe renal insufficiency; 7. History of alcoholism or drug dependence; 8. Abuse or long-term use of narcotic, sedative and analgesic drugs; 9. Those with a history of mental illness; 10. Participants in any drug clinical trials within 1 month prior to screening; 11. Pregnant and lactating women; Fertile women or men were unwilling to use contraception throughout the trial; Subjects (including male subjects) who have a pregnancy plan within 1 month after the trial; 12. Subjects who have any other factors that the Investigator considers inappropriate for participation in the study.

Design outcomes

Primary

MeasureTime frame
Loss of consciousness time;Wake up of time;Use of narcotic drugs;MOAA/S;

Countries

China

Contacts

Public ContactZhentao Sun

The First Affiliated Hospital of Zhengzhou University

fccsunzt@zzu.edu.cn+86 136 0345 5483

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026